Find Funding Opportunities

This FOA is intended to: (1) increase our understanding of how music positively affects the brain, body, and behavior and (2) use that knowledge to enhance health and/or treat specific diseases and disorders. Proposed R01 projects could investigate the mechanisms by which music affects the brain to improve health either in healthy or diseased states. Proposed R01 projects could also focus on the development or refinement of specific musical interventions relevant to the participating institutes, agencies, and offices. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

This FOA is intended to: (1) increase our understanding of how music positively affects the brain, body, and behavior and (2) use that knowledge to enhance health and/or treat specific diseases and disorders. R21 projects could propose exploratory investigations to define the mechanisms by which music affects the brain to improve health either in healthy or diseased states. Proposed R21 projects could explore the early stage development or refinement of specific musical interventions relevant to the participating institutes, agencies and offices. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

Notice Change Key Dates PAR-18-628 NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional)" Notice Number: NOT-NS-20-090 Key Dates Release Date: August 11, 2020 Related Announcements PAR-18-628 - NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-628 "NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional)(changes shown below bold italics). This Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: April 5, 2021. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Codrin Lungu, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: lunguci@ninds.nih.gov

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-001 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)" Notice Number: NOT-NS-20-097 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-001 - NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner.  Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)".  late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-097) be submitted, it not required. the September 28, 2021, September 28, 2022, application due date(s), NIH Policy Late Submission Grant Applications NOT-OD-15-039 applies. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement."  Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-002 NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)" Notice Number: NOT-NS-20-098 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-002 - NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner. Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-098) be submitted, it not required. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement." Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov

Notice Change Key Dates PAR-18-563 NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional)" Notice Number: NOT-NS-20-099 Key Dates Release Date: August 11, 2020 Related Announcements PAR-18-563 - NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-563 "NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional)". Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: April 5, 2021. Changes the FOA shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Claudia Scala Moy, Ph.D.  National Institute Neurological Disorders & Stroke NINDS) Telephone: 301-496-9135  Email: moyc@ninds.nih.gov

Notice Change Key Dates PAR-18-528 NeuroNEXT Clinical Trials U01 Clinical Trial Optional)" Notice Number: NOT-NS-20-084 Key Dates Release Date: August 10, 2020 Related Announcements PAR-18-528 - NeuroNEXT Clinical Trials U01 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-528 "NeuroNEXT Clinical Trials U01 Clinical Trial Optional)" changes show below bold italics). Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: February 5, 2021 Renewal, Resubmission, Revision Due Date: March 5, 2021. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date March 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Codrin Lungu, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: lunguci@ninds.nih.gov

Notice Clarification NIH BRAIN Initiative Institutional Letter RFA-NS-19-043 RFA-NS-19-044" K99/R00 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity" Notice Number: NOT-NS-20-094 Key Dates Release Date: August 5, 2020 Related Announcements RFA-NS-19-043 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed) RFA-NS-19-044 - BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) Purpose Notice to clarify placement inclusion the Institutional Letter RFA-NS-19-043 BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed) RFA-NS-19-044- BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Required). current language reads: Section IV. Application Submission Information Project Information Institutional Letter: Applicants required attach letter the institution explaining the candidate's participation further goals the BRAIN Initiative Postdoctoral Career Transition Award, consistent the Notice NIH's Interest Diversity NOT-OD-18-210). letter the institution must on institutional letterhead scanned that institutional official signature visible. Name PDF-formatted letter Institutional_Ltr.pdf". letter limited 1 page. Due Forms-F application package changes, language been removed. Applicants should refer the PHS 398 Career Development Award Supplement Form instructions this letter. Please updated instructions below. language been modified read: Section IV. Application Submission Information PHS 398 Career Development Award Supplemental Form Environment Institutional Commitment Candidate Section outlined the SF424 form instructions, applicants diversity-related FOAs must complete 12. Description Candidate’s Contribution Program Goals” attachment: sponsoring institution must provide document institutional letterhead explains the candidate’s participation further goals the career development program promote diversityin BRAIN Initiative research. Description Candidate’s Contribution Program Goals” attachment must dated signed an institutional official. most cases, will the dean the chairman the department. signature must appear over signer's name title the end the statement. Attach information a PDF file. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: BRAINDIVERSITYK99R00@nih.gov

Solicitation Nominations the 2021 National Institute Neurological Disorders Stroke NINDS) Landis Award Outstanding Mentorship Notice Number: NOT-NS-20-093 Key Dates Release Date: July 29, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose Excellent mentorship superior training critical the development exceptional future scientists. recognize crucial role great mentors play the development future leaders neuroscience, National Institute Neurological Disorders Stroke NINDS) created Landis Award Outstanding Membership. award provides 100,000.00 direct costs) up five 5) faculty members, are considered be outstanding mentors trainers, help foster research career development additional students post-doctorates. NINDS hopes this tangible award impress upon scientific community a whole, faculty institutional leaders particular, high value NINDS places outstanding training mentorship the need faculty institutions emphasize reward dedication mentorship, addition outstanding research accomplishments. Selection this award based nomination those have first-hand knowledge an individual's outstanding mentorship. Current former trainees nominate faculty members have served their mentors. Faculty members nominated two more mentees then invited submit additional information needed the selection process. Eligible individuals this award must in tenure-track equivalent faculty position hold active NINDS R01, R35, U01, U54, P01,DP1, DP2 equivalent, 4-5 year duration NIH award, at least year left their grant June 2021. full details the award, the selection process be found at Landis Mentor Award. Because outstanding mentors exist each career stage, have different levels mentorship accomplishments, NINDS rotates eligibility requirements year. 2018, NINDS awards junior faculty mentors the 5th - 12th year the start their first tenure track equivalent position). 2019, NINDS awards mid-career faculty mentors the 13th - 20th year the start their first tenure track equivalent position). 2020, NINDS awards senior faculty 21 years more the start their first tenure track equivalent position). Landis Awardees be found Landis Mentor Award. this notice, NINDS invites nominations outstanding mentors are 5-12 years the start their first tenure-track equivalent faculty position i.e., start date their first tenure-track equivalent faculty position between 2008-2015). Nomination Nominations the NINDS Landis Mentor Award be accepted ONLY current former trainees the nominated individual. nominate current former mentor, individuals should visit Landis Mentor Award and complete nomination form by December 15, 2020. following information be requested: Nominator's name current position Name individual being nominated nominee) Current institution email address nominee Start date nominee's first tenure-track equivalent position Relationship nominator nominee dates mentorship, position nominator mentored nominee e.g. Former Current Graduate Student, Postdoctoral Fellow, etc.]) Statement describing basis the nomination. description should include: made/makes nominated individual exceptional mentor/trainer; are specific examples extraordinary dedication mentorship personally experienced witnessed; does individual to ensure trainees conduct highest quality research respect scientific premise, experimental design analysis; were specific nominee activities influenced nominator's growth a neuroscientist. a nomination be considered, of above information must provided via nomination form found at Landis Mentor Award. Selection NINDS consider number characteristics define outstanding mentorship guide final selection Landis Awardees. include: actively cultivating mentees pursuit scientific excellence, whether basic, translational, clinical research, rigor experimental design, analysis, interpretation; investing their mentee’s scientific professional development career progress, regardless their ultimate career interest; challenging mentees achieve full scientific potential, includes completion significant research projects meaningful contributions the biomedical research community; contributing excellence research training environments strengthening research enterprise inclusion people diverse backgrounds. is expected potential Landis awardees demonstrate support outstanding research training programs include diversity inclusion all career levels. Inquiries Please direct inquiries to: Stephen Korn National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email:korns@ninds.nih.gov

Notice Change Key Dates PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Notice Number: NOT-NS-20-086 Key Dates Release Date: July 10, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; September 9, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date September 10, 2020 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; October 8, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date October 9, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email: jettd@ninds.nih.gov